» Articles » PMID: 33298880

PTRH2: an Adhesion Regulated Molecular Switch at the Nexus of Life, Death, and Differentiation

Overview
Date 2020 Dec 10
PMID 33298880
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Peptidyl-tRNA hydrolase 2 (PTRH2; Bit-1; Bit1) is an underappreciated regulator of adhesion signals and Bcl2 expression. Its key roles in muscle differentiation and integrin-mediated signaling are central to the pathology of a recently identified patient syndrome caused by a cluster of Ptrh2 gene mutations. These loss-of-function mutations were identified in patients presenting with severe deleterious phenotypes of the skeletal muscle, endocrine, and nervous systems resulting in a syndrome called Infantile-onset Multisystem Nervous, Endocrine, and Pancreatic Disease (IMNEPD). In contrast, in cancer PTRH2 is a potential oncogene that promotes malignancy and metastasis. PTRH2 modulates PI3K/AKT and ERK signaling in addition to Bcl2 expression and thereby regulates key cellular processes in response to adhesion including cell survival, growth, and differentiation. In this Review, we discuss the state of the science on this important cell survival, anoikis and differentiation regulator, and opportunities for further investigation and translation. We begin with a brief overview of the structure, regulation, and subcellular localization of PTRH2. We discuss the cluster of gene mutations thus far identified which cause developmental delays and multisystem disease. We then discuss the role of PTRH2 and adhesion in breast, lung, and esophageal cancers focusing on signaling pathways involved in cell survival, cell growth, and cell differentiation.

Citing Articles

Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours.

Ghosh A, Chaubal R, Das C, Parab P, Das S, Maitra A Commun Biol. 2025; 8(1):207.

PMID: 39930151 PMC: 11811163. DOI: 10.1038/s42003-025-07606-x.


An Update of Phenotypic-Genotypic IMNEPD Cases and a Bioinformatics Analysis of the New Gene Variants.

Sharkia R, Vuillaume M, Jain S, Mahajnah M, Stoeva R, Guichet A Genes (Basel). 2025; 15(12.

PMID: 39766776 PMC: 11675358. DOI: 10.3390/genes15121508.


Severe Respiratory and Swallowing Disorders in Infantile-Onset Multisystem Neurologic, Endocrine, and Pancreatic Disease Type 1: Two Cases.

Berling E, Latour P, Loiselet K, Guemy C, Vidoni L, Romero N Neurol Genet. 2024; 10(5):e200178.

PMID: 39176129 PMC: 11341004. DOI: 10.1212/NXG.0000000000200178.


Simultaneous screening of overexpressed genes in breast cancer for oncogenic drivers and tumor dependencies.

Mofunanya A, Cameron E, Braun C, Celeste F, Zhao X, Hemann M Sci Rep. 2024; 14(1):13227.

PMID: 38851782 PMC: 11162420. DOI: 10.1038/s41598-024-64297-w.


A Novel PTRH2 Gene Mutation Causing Infantile-onset Multisystem Neurologic, Endocrine, and Pancreatic Disease in a Bahraini Patient.

Isa H, Khalaf S, Janahi S, Naser M, Al Hamad N, Alhaddar H Oman Med J. 2024; 39(1):e599.

PMID: 38510576 PMC: 10951560. DOI: 10.5001/omj.2024.08.


References
1.
Krueger B, Burne J, Raff M . Evidence for large-scale astrocyte death in the developing cerebellum. J Neurosci. 1995; 15(5 Pt 1):3366-74. PMC: 6578202. View

2.
Karczewski K, Francioli L, Tiao G, Cummings B, Alfoldi J, Wang Q . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443. PMC: 7334197. DOI: 10.1038/s41586-020-2308-7. View

3.
Jenning S, Pham T, Ireland S, Ruoslahti E, Biliran H . Bit1 in anoikis resistance and tumor metastasis. Cancer Lett. 2013; 333(2):147-51. PMC: 3651913. DOI: 10.1016/j.canlet.2013.01.043. View

4.
Karmali P, Brunquell C, Tram H, Ireland S, Ruoslahti E, Biliran H . Metastasis of tumor cells is enhanced by downregulation of Bit1. PLoS One. 2011; 6(8):e23840. PMC: 3160313. DOI: 10.1371/journal.pone.0023840. View

5.
Fan T, Chen J, Zhang L, Gao P, Hui Y, Xu P . Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway. Mol Cancer. 2016; 15:23. PMC: 4782287. DOI: 10.1186/s12943-016-0507-5. View